Eli Lilly announced the company has started an early-stage trial to test its potential treatment for coronavirus. Yahoo Finance’s Anjalee Khemlani breaks down the latest developments.

from Yahoo Finance https://ift.tt/2MgArtd

Last week the SpaceX Crew Dragon capsule successfully launched into orbit. Yahoo Finance’s On The Move panel share the details.

from Yahoo Finance https://ift.tt/2MlJCIW

Shares in Minerva Neurosciences Inc. (NERV) tanked 72% after the company's experimental drug roluperidone tailored for the treatment of schizophrenia did not meet its primary and key secondary endpoints in a Phase 3 trial.The stock sank 72% to $3.71 on Friday. The clinical-stage biotech company said the trial conducted among 513 patients did not demonstrate “statistically significant difference from the placebo” in narrowing disease symptoms at week 12 of the treatment. However, the study did show that the roluperidone experimental drug was generally well tolerated, the company said.“Even though this study didn’t achieve its primary and key secondary endpoints, primarily due to a larger than expected placebo effect at Week 12, results obtained with the 64 mg dose including the early onset of effect and functional improvement as measured by PSP suggest roluperidone merits continued investigation for the treatment of primary negative symptoms,” said Remy Luthringer, Executive Chairman and CEO of Minerva. “We intend to consult with the US FDA about the next steps in the development of roluperidone for this indication after we complete the analysis of the study data.”Roluperidone is being developed as a treatment for the negative symptoms of schizophrenia that can persist chronically throughout patients’ lifetimes and contribute to poor quality of life and functional outcomes. The experimental drug has in the past been shown to potentially block serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety.In reaction to the announcement, five-star analysts Myles Minter at William Blair and Biren Amin at Jefferies on Friday both cut Minerva's stock to Hold from Buy. Amin, who has a $2 price target on the stock does not believe the FDA will consider benefit on a secondary endpoint when a study fails on a primary endpoint, leaving an unclear path for the drug.The rest of Wall Street analysts have 3 Buy ratings on the stock adding up to a Moderate Buy consensus. The $15.75 average analyst price target now implies a staggering 325% upside potential in the shares in the coming 12 months. (See Minerva stock analysis on TipRanks).  Related News: Moderna Embarks On Phase 2 Study Of Covid-19 Candidate; Shares Pop 11% Efgartigimod’s Positive Data Is Good News for Momenta’s Nipocalimab Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses; Top Analyst Ramps More recent articles from Smarter Analyst: * Abiomed’s Heart Pump Gets FDA Emergency Use Status For Covid-19 Patients * Eli Lilly’s Taltz Injection Gets FDA Nod For Inflammatory Spine Arthritis Treatment * Zynga Snaps Up Peak For $1.8B In Its Largest Deal To Date; Shares Up 7% * Eli Lilly Starts Dosing Patients In World’s First Covid-19 Antibody Trial

from Yahoo Finance https://ift.tt/3drhXSO

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

from Yahoo Finance https://ift.tt/2ZYW5KC

The treatment, Ibrance, was being tested along with the standard of care for early breast cancer in men and women, against standard of care alone, the company said on Friday. The study was broadly seen to have a high probability of success readout, but the early failure represents a meaningful setback for Pfizer, JP Morgan analysts said in a note, cutting its price target on the stock by $1 to $37.

from Yahoo Finance https://ift.tt/36NeQSD

Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Heidi Chung discuss the market action for Tesla.

from Yahoo Finance https://ift.tt/2ZWhkg3

Yahoo Finance’s Jared Blikre breaks down the latest on U.S, China relations.

from Yahoo Finance https://ift.tt/2zPZEYO

In this article you are going to find out whether hedge funds think Keysight Technologies Inc (NYSE:KEYS) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

from Yahoo Finance https://ift.tt/2ApDVqy

In this article we will check out the progression of hedge fund sentiment towards L3Harris Technologies, Inc. (NYSE:LHX) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

from Yahoo Finance https://ift.tt/2ApGybI

The nation continues to grapple with civil unrest over the killing of George Floyd in police custody. Many leaders across retail, tech and banking are speaking out over the weekend and Monday morning as protests continue. Yahoo Finance’s Alexis Christoforous and Emily McCormick share the details.

from Yahoo Finance https://ift.tt/2AohqCl